Loading
Individualised mRNA cancer vaccines take weeks to manufacture and work best against minimal residual disease. Making the vaccine at surgery and giving it only when a blood tumour DNA test turns positive matches both facts and concentrates the cost on the minority who will relapse.
An individualised mRNA neoantigen vaccine produced immune responses and prolonged recurrence-free survival in a randomised phase 2 in ctDNA-positive resected pancreatic and colorectal cohorts, and adjuvant melanoma data support the setting. Manufacturing time is the practical constraint, which a manufacture-at-surgery, deploy-on-ctDNA-positivity design resolves, and it concentrates cost on the minority who will relapse.
Shares Moderna, Autogene cevumeran, Intismeran autogene, BioNTech.
Shares Autogene cevumeran, Intismeran autogene, BioNTech, Neoantigen.
Shares Autogene cevumeran, BioNTech, Neoantigen, Personalised neoantigen (mRNA) vaccines.
Shares Autogene cevumeran, Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Melanoma.
Shares Moderna, BioNTech, Neoantigen, Personalised neoantigen (mRNA) vaccines.
Shares Moderna, Autogene cevumeran, Intismeran autogene, BioNTech.
Shares Autogene cevumeran, BioNTech, Personalised neoantigen (mRNA) vaccines, Minimal / molecular residual disease (MRD).
Shares Moderna, Intismeran autogene, Neoantigen, Personalised neoantigen (mRNA) vaccines.